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Review Article
Guidelines on eosinophilic esophagitis:
evidence-based statements and
recommendations for diagnosis and
management in children and adults
Alfredo J Lucendo1,2, Javier Molina-Infante2,3, A´ngel Arias2,4,
Ulrike von Arnim5, Albert J Bredenoord6, Christian Bussmann7,
Jorge Amil Dias8, Mogens Bove9, Jesu´s Gonza´lez-Cervera2,10, Helen Larsson9,
Stephan Miehlke11, Alexandra Papadopoulou12, Joaquı´n Rodrı´guez-Sa´nchez13,
Alberto Ravelli14, Jukka Ronkainen15, Cecilio Santander2,16,
Alain M Schoepfer17, Martin A Storr18, Ingrid Terreehorst19,
Alex Straumann20 and Stephen E Attwood21
Abstract
Introduction: Eosinophilic esophagitis (EoE) is one of the most prevalent esophageal diseases and the leading cause of
dysphagia and food impaction in children and young adults. This underlines the importance of optimizing diagnosys and
treatment of the condition, especially after the increasing amount of knowledge on EoE recently published. Therefore, the
UEG, EAACI ESPGHAN, and EUREOS deemed it necessary to update the current guidelines regarding conceptual and
epidemiological aspects, diagnosis, and treatment of EoE.
Methods: General methodology according to the Appraisal of Guidelines for Research and Evaluation (AGREE) II and the
Grading of Recommendations Assessment, Development, and Evaluation (GRADE) system was used in order to comply with
current standards of evidence assessment in formulation of recommendations. An extensive literature search was conducted
up to August 2015 and periodically updated. The working group consisted of gastroenterologists, allergists, pediatricians,
otolaryngologists, pathologists, and epidemiologists. Systematic evidence-based reviews were performed based upon rele-
vant clinical questions with respect to patient-important outcomes.
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Results: The guidelines include updated concept of EoE, evaluated information on disease epidemiology, risk factors,
associated conditions, and natural history of EoE in children and adults. Diagnostic conditions and criteria, the yield of
diagnostic and disease monitoring procedures, and evidence-based statements and recommendation on the utility of the
several treatment options for patients EoE are provided. Recommendations on how to choose and implement treatment and
long-term management are provided based on expert opinion and best clinical practice.
Conclusion: Evidence-based recommendations for EoE diagnosis, treatment modalities, and patients’ follow up are proposed
in the guideline.
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Introduction
Eosinophilic esophagitis (EoE) is an inﬂammatory con-
dition of the esophagus that, today, constitutes the
most prevalent cause of chronic esophagitis after gas-
troesophageal reﬂux disease (GERD) and the leading
cause of dysphagia and food impaction in children and
young adults. The ﬁrst EoE cases appeared in the late
1970s and EoE was deﬁned as a distinct clinicopatho-
logic syndrome in the early 1990s.1,2 From that
moment, its growing recognition and exponential
increase in the number of identiﬁed patients from
many continents makes EoE both a scientiﬁc and
health challenge.
A growing amount of literature on EoE has been
published from the identiﬁcation of the disease, includ-
ing several consensus documents by groups of experts
and clinical practice guidelines developed under the
auspices of American and European scientiﬁc societies
for children and adult patients.3–6 However, the huge
amount of knowledge achieved in the last 5 years,
including several randomized controlled trials (RCTs)
and systematic reviews, have determined that published
guidelines on EoE could be currently outdated. In this
regard, no previous guidelines have used speciﬁc meth-
ods suited to the purpose of establishing the quality
of the evidence and the weight of the statements
and recommendations provided.7 The use of
GRADE (Grading of Recommendations Assessment,
Development, and Evaluation) technology has been
recommended in recent years as a standard tool for
the development of clinical practice guides.8 The pre-
sent guide is the ﬁrst one developed in EoE using this
methodology.
The statements and recommendations in the present
document are meant to be used by physicians and other
health professionals involved in the management of
EoE. Epidemiological, etiological, and pathogenic
aspects are also reviewed, and the currently preferred
approach to diagnosis and treatment of the disorder is
deﬁned. Whenever possible, the speciﬁc statements or
recommendations were based on the best available evi-
dence, and when such evidence was either not available
or was found to be inconsistent, the recommendations
were established by consensus among the authors
according to expert opinion and best clinical practice.
Aims and methodology
This practical guide aims to provide a structured frame-
work for the integrative management of EoE in chil-
dren and adults, for clinicians involved in their
management, including gastroenterologists, allergists,
pediatricians, otorhinolaryngologists, pathologists, pri-
mary care practitioners, and dietitians.
Participants in the consensus
A task force of 21 physicians and researchers with
recognized expertise in the clinical evaluation, endos-
copy, histopathology, epidemiology, physiopathology,
allergy, and treatment of EoE was gathered to address
speciﬁc clinically relevant topics.
First, a preliminary list of topics to be covered by the
guidelines and its general goals was set by the Steering
Committee (AJL, JM-I, AJB, JG-C, AMS, UVA, AS,
SA) and surveyed to a panel integrated for adult
patients with EoE, as well as parents of aﬀected chil-
dren, in order to collect their opinions on the import-
ance of each statement, the need of being included in a
practice guide and its potential impact on clinical prac-
tice. The results of the survey were considered to reﬁne
the ﬁnal list of topic, but EoE patients and parents did
not participate in guidelines development. The reﬁned
list of topics was then submitted to all the participating
authors, integrated as a Working Committee, and par-
ticipating on behalf of the United European
Gastroenterology (UEG), The European Society of
Pediatric Gastroenterology, Hepatology and Nutrition
(ESPGHAN), the European Academy of Allergy and
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Clinical Immunology (EAACI), and the European
Society of Eosinophilic Oesophagitis (EUREOS).
Secondly, the Working Committee drafted the ﬁrst
document that was revised in depth by the Steering
Committee in a face to face meeting, revising the
terms of statement wording, strength of recommenda-
tion and quality of evidence. It was submitted to be
reviewed by the Working Committee, who prepared a
second version of the document. This document was
submitted to further review by an External Review
Committee, which included gastroenterologists, pediat-
ricians, allergists, pathologist and EoE patients and
parents. Finally, the Working Committee drafted the
ﬁnal document.
Literature search
A formal systematic review of the literature was carried
out for every statement. MEDLINE (accessed via
PubMed) and EMBASE electronic databases, as well
as The Cochrane Database of Systematic Reviews (The
Cochrane Library) and the Cochrane Central Register
of Controlled Trials (CENTRAL), were consulted cov-
ering the period up until August 2015, with no restric-
tion of languages, and periodically updated (Annex A).
A review of the citations to identify potentially relevant
articles was also carried out. Priority was placed on the
identiﬁcation of systematic reviews and other docu-
ments oﬀering a critical synthesis of the scientiﬁc litera-
ture, as well as randomized clinical trials, whenever
possible. Librarian and methodological support was
provided by experts at the Spanish Society of
Digestive Diseases (SEPD).
Review and assessment of evidence
The Working Committee followed the GRADE meth-
odology (see www.gradeworkinggroup.org) to assess
the quality (certainty) of evidence, 8 and classiﬁed the
recommendations for the diﬀerent clinical scenarios
into four clear and easy-to-understand ﬁnal categories:9
strong recommendation for an intervention, implying
for the clinician to do it; weak recommendation for an
intervention, which implies to probably do it; weak
against an intervention, implying to probably do not
do it; and strong against an intervention, implying not
to do it.
Deﬁned using the GRADE methodology, these rec-
ommendations were mainly, but not solely, based on
the strict assessment of the quality of the evidence
(high, moderate, low, or very low quality). The quality
of the evidence could be downgraded as a result of
limitations in the study design or in its implementation,
imprecision of estimates (wide conﬁdence intervals),
variability in the results, indirectness of the evidence,
or publication bias; or upgraded because of a very large
magnitude of eﬀects, a dose-response gradient, or if all
the plausible biases would reduce an apparent treat-
ment eﬀect. Furthermore, the recommendations were
also based on some other factors, such as desirable
and undesirable consequences of alternative manage-
ment strategies, variability in values and preferences,
and the use of resources (costs). GRADE assessments
were then reviewed and agreed upon by voting mem-
bers of the Working Committee at a ﬁnal face to face
meeting. Finally, the Agree II instrument (www.agree-
collaboration.org) was used to ensure the high quality
of our Clinical Practice Guideline, which was evaluated
by the authors and the Steering Committee.
Consensus process
A full-day consensus meeting was held in Vienna,
Austria, on 16 October 2016 in order to vote the state-
ments and recommendations based on the nominal
group technique.10 The participants decided whether
they considered the statement/recommendation to be
adequate, based on a six-point Likert scale (1: strongly
disagree; 2: quite disagree; 3: somewhat disagree; 4:
somewhat agree; 5: quite agree; 6: strongly agree),
and suggested changes or new ones. After voting, the
work groups revised the statement and recommenda-
tions according to the comments received, and a
second vote was then held. The statements and recom-
mendations resulting from the second vote were dis-
cussed and approved during this physical presence
meeting. A statement/recommendation was approved
if over 75% of the participants agreed with it (Likert
score of 4–6).
The voting group was composed by 15 members
integrated in the steering and Working Committees,
including gastroenterologists, pediatricians, allergists,
and methodologists, all of them settled in Europe
with expertise in EoE. Although there were no diet-
itians or EoE patients’ representatives, the impact of
the recommendations on dietitians, as well as commu-
nity resources and local availability, was discussed prior
to voting for each statement.
Statements and recommendations
Each statement/recommendation is accompanied by
the level of evidence (LE: high, moderate, low or very
low), the result of the vote (percentage agreement) at
the consensus meeting, and discussion of the corres-
ponding evidence. The strength of recommendation
(SR: strong or weak) using the GRADE approach
was only given for studies on the accuracy of diagnostic
procedures, or which assessed the eﬃcacy of a treat-
ment, as mentioned above. This kind of classiﬁcation
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is easy to understand and is ﬂexible, since it can be
applied to the diﬀerent clinical scenarios.
Role of the funding sources
The SEPD administered all aspects of the meeting,
which was funded by the UEG as a part of the Link
Award program, with no external funding sources.
Recommendation statements
Epidemiological and clinical-focused questions formed
the basis of the systematic literature reviews (see
Appendix A in the online supplementary material).
The working group formulated 45 recommendations
based on these reviews (see Table 1).
Section A. EoE concept and epidemiology
What is the current definition of EoE?. Statement 1: EoE
represents a chronic, local immune-mediated esopha-
geal disease, characterized clinically by symptoms
related to esophageal dysfunction and histologically
by eosinophil-predominant inﬂammation. Other sys-
temic and local causes of esophageal eosinophilia
should be excluded. Clinical manifestations or patho-
logic data should not be interpreted in isolation.
LE: NA; Agreement: 100%, votes: strongly agree
(100%).
Summary of the evidence: EoE as a distinct entity was
ﬁrst described in 1993 and 1994.1,2 Guidelines for the
disease, which were originally written in 2007,3 were
updated in 2011 when a ﬁrst formal deﬁnition of the
disease was provided.4 EoE was deﬁned as a chronic
immune/antigen-mediated disease, isolated to the
esophagus, and characterized by symptoms of esopha-
geal dysfunction and eosinophil-predominant inﬂam-
mation on esophageal biopsy. It is important to stress
that other systemic and local causes of esophageal
eosinophilia should be excluded (see Supplementary
table 1).
From 2011, the most relevant advances in the deﬁn-
ition of EoE have been related to evolving consider-
ations of the trial of proton pump inhibitor (PPI)
therapy as a diagnostic criteria and the disease pheno-
type termed PPI-responsive esophageal eosinophilia
(PPI-REE). Aside from clinic and histologic features,
the original deﬁnition diagnostic criteria for EoE in
2007 included a PPI trial:3 only patients unresponsive
to PPI therapy (or alternatively with a normal esopha-
geal pH monitoring) could be diagnosed of EoE. These
criteria were based on the assumption that only GERD,
as an acid-related disorder, could respond to the acid
suppressive eﬀect of PPIs, and considered GERD and
EoE as mutually exclusive disorders. The description of
a new potential disease phenotype in 2011, termed PPI-
REE, was acknowledged as one of the major additions
to previous knowledge.4 It refers to patients with clinic,
endoscopic and histologic features of EoE which com-
pletely remit on PPI therapy, albeit not necessarily
associated to GERD.11 Consequently, PPI-REE
replaced GERD as the main diﬀerential diagnosis of
EoE and pH monitoring was retracted as a diagnostic
criterion. However, all iterations of guidelines since
2011 have systematically maintained a PPI trial as a
diagnostic criterion,4–6 since PPI-REE and EoE were
considered distinct disorders as they showed a diﬀerent
response to the PPI trial.
Since 2011, solid evidence, mostly from adult
patients, has highlighted that PPI-REE and EoE are
virtually indistinguishable from one another, even at
the genetic level, and very diﬀerent from GERD.12
No other inﬂammatory disease than PPI-REE is
deﬁned by its response to a single medication, instead
of by its clinic, endoscopic, bioptic, molecular, genetic,
and therapeutic overlap with EoE. Therefore, the main
novelty in these guidelines is the retraction of the term
PPI-REE and the consideration of PPI therapy not as a
diagnostic criterion for EoE, but rather as a therapeutic
agent. Consequently, these guidelines consider that
clinical and histological features suggestive of EoE
may remit with treatment of PPI therapy, topical ster-
oids or elimination diets. Since it still remains unknown
whether the esophageal immune response in patients
who respond to PPI therapy is triggered by GERD,
food allergens or the combination of both factors, the
term ‘‘antigen’’ has now been removed from the
deﬁnition.
Does response to PPI therapy rule out EoE?. Statement 2:
Adult patients achieving clinical and histological remis-
sion on PPI therapy are part of the EoE continuum,
rather than a separate entity. Responders and non-
responders to PPI therapy show overlapping pheno-
typic, genetic, and mechanistic features. More data
are required in children.
LE: moderate. Agreement: 100%, votes: strongly
agree (100%).
Summary of evidence: Over the past few years, mul-
tiple studies have closed the gap between PPI-REE and
EoE. Both disorders have been repeatedly reported to
be phenotypically indistinguishable, in terms of clinical,
endoscopic, pH monitoring, histological, and molecular
data.11–22 A major contribution in this ﬁeld has been
the identiﬁcation of a similar pattern of gene up- and
down-regulation comprising the EoE hallmark gene
signature in EoE and PPI-REE patients, but not in
GERD patients.21 After in vitro demonstration of
potential anti-inﬂammatory eﬀects of PPIs,22 recent
clinical studies have shown PPI monotherapy
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Table 1. Summary of European statements and recommendations on the management of EoE.
Section and
number Statements
Level of
evidence
Strength of
recommendation Key references
Section A EoE concept and epidemiology
1 EoE represents a chronic, local immune-mediated
esophageal disease, characterized clinically by
symptoms related to esophageal dysfunction
and histologically by eosinophil-predominant
inflammation. Other systemic and local causes
of esophageal eosinophilia should be excluded.
Clinical manifestations or pathologic data
should not be interpreted in isolation
NA NA Expert opinion
2 Adult patients achieving clinical and histological
remission on PPI therapy are part of the EoE
continuum, rather than a separate entity.
Responders and non-responders to PPI therapy
show overlapping phenotypic, genetic, and
mechanistic features. More data are required in
children.
Moderate NA 11, 12, 17, 19, 21, 22
3 EoE and GERD are different entities and may
coexist, either unrelated or interacting
bidirectionally.
Moderate NA 26, 30
4 The incidence of EoE has increased and currently
varies widely from 1 to 20 new cases per 100,000
inhabitants per year (mean value 7). Prevalence
rates ranges between 13 and 49 cases per
100,000 inhabitants
Moderate NA 44, 45
5 The frequency of EoE in adults with esophageal
symptoms undergoing an upper endoscopy is
7%. This frequency may rise up to 23% and
50% in patients with dysphagia and food
impaction, respectively. Further data in children
are required.
Moderate NA 46, 53, 54, 56, 60, 61
6 EoE may occur at any age with a rising incidence in
children with age and a peak in adults at 30–50
yrs
Moderate NA 62, 63, 64
7 Male gender is a strong risk factor for EoE both in
children and adults.
High NA 45
8 Rhinitis, asthma and eczema are significantly more
common in EoE patients compared to the gen-
eral population. However, it remains unproven
that atopy predisposes to EoE.
Moderate NA 79
9 EoE is a distinct form of food allergy. IgE-mediated
food allergies are common in EoE patients.
High NA 91
10 EoE and celiac disease are independent disorders. High NA 95
11 EoE appears to have no causal or temporal rela-
tionship with hypereosinophilic syndromes,
inflammatory bowel disease, esophageal atre-
sia, and connective tissue disorders.
Low NA 99, 108, 110, 116
Section B Diagnosis
12 In older children and adults with EoE solid food
dysphagia, food impaction, and non-swallow-
ing associated chest pain are the most com-
monly reported symptoms. In younger children
and infants the most common symptoms
High NA 64, 87, 118, 119, 120
(continued)
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Table 1. Continued
Section and
number Statements
Level of
evidence
Strength of
recommendation Key references
reported are reflux-like symptoms, vomiting,
abdominal pain, food refusal and failure to
thrive.
13 Al least six biopsies should be taken from different
locations, focusing on areas with endoscopic
mucosal abnormalities.
Moderate Strongly in favor 121, 122, 129, 131
14 The accepted threshold for eosinophil density for
the diagnosis of EoE is 15 eosinophils per high
power field (standard size of 0.3mm2) in
esophageal mucosa, taken as the peak concen-
tration in the specimens examined.
Moderate Strongly in favor 132, 135, 136, 140
15 Hematoxylin-eosin staining is sufficient for histo-
logical assessment of EoE in routine clinical
practice.
Low Weakly against 141, 144, 147
16 Besides peak eosinophil count, additional histo-
logical features may include eosinophil micro-
abscesses, basal zone hyperplasia, dilated
intercellular spaces, eosinophil surface layering,
papillary elongation, and lamina propria
fibrosis.
Moderate Weakly in favor 149, 150
17 Currently, noninvasive biomarkers are not accurate
to diagnose or monitor EoE. Some minimal
invasive diagnostic tools show promise and
merit further evaluation
Moderate Strongly against 159, 161, 163, 164, 165
18 Symptoms do not correlate accurately with histo-
logic disease activity, so histology currently
continues to be necessary to monitor the
disease.
Moderate Weakly in favor 166, 172
19 Endoscopic findings alone do not reliably establish
a diagnosis of EoE. Their value to assess disease
activity needs further evaluation.
Low Weakly in favor 131, 183, 184
Section C Natural history
20 Untreated EoE is usually associated with persistent
symptoms and inflammation, leading to
esophageal remodeling resulting in stricture
formation and functional abnormalities. There
is some evidence that effective anti-inflamma-
tory treatment may limit progression.
Moderate NA 64, 99, 185, 188, 189,
192, 151, 152
21 EoE significantly impacts health-related quality of
life of patients, impairing their social and psy-
chological functioning.
Moderate NA 194, 195, 197, 198
22 There is no evidence so far that EoE is a pre-
malignant condition.
Moderate NA 207
Section D Treatment
23 PPI therapy induces clinical and histological
remission in a proportion of pediatric and adult
patients with EoE.
Moderate Strongly in favor 211, 212, 215
24 In PPI responders, long-term PPI therapy is
effective in maintaining remission
Low Strongly in favor 214, 219, 220
25 Systemic steroids are not recommended in EoE Moderate Strongly against 221
(continued)
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Table 1. Continued
Section and
number Statements
Level of
evidence
Strength of
recommendation Key references
26 Topical corticosteroids are effective for induction of
histological remission in both pediatric and
adult EoE patients.
High Strongly in favor 226, 227, 228, 229
27 In steroids responsive patients, long-term therapy
with topical corticosteroids is effective in
maintaining remission in a proportion of
patients.
Low Strongly in favor 224, 230, 231
28 Swallowed topical corticosteroids seem to have a
favorable safety profile in the treatment of EoE,
with no serious side effects reported.
Esophageal candidiasis, mostly incidental, may
occur in up to 10% of patients.
Moderate NA 22, 230, 231
29 There is a limited place for elemental diet in EoE,
which should only be considered after failure of
properly performed medical treatment and/or
elimination diet. Elemental diet induces histo-
logic remission in up to 90% of pediatric and
adult EoE patients. There is limited information
regarding symptoms.
Low Weakly against 63, 80, 235, 238, 239
30 Food allergy testing-based elimination diet
induces histologic remission in less than one
third of adult patients. This rate may be higher
in pediatric patients.
Moderate Strongly against 245, 239, 248, 250
31 The utility of allergy tests in the identification of
food triggers of EoE is consistently low in adults
and variable in children.
Low Strongly against 237, 245, 255, 256
32 An empiric six-food group elimination diet induces
histologic remission in around three quarters of
pediatric and adult patients.
Moderate Weakly in favor 84, 85, 239, 260
33 In adult patients, an empiric four-food elimination
diet achieves remission in half of the patients,
whereas a two-food elimination diet (animal
milk and gluten-containing cereals) may be still
effective in 40% of patients.
Moderate Weakly in favor 250, 261, 265
34 Prolonged avoidance of triggering foods may lead
to drug-free sustained clinical and histological
remission of EoE.
Low Strongly in favor 85, 260, 268
35 Endoscopic dilation improves dysphagia in up to
three quarters of adult EoE patients with
reduced esophageal caliber, without having an
effect on the underlying esophageal
inflammation.
Moderate Strongly in favor 269, 274
36 Endoscopic dilation in EoE is a safe procedure, with
a risk of esophageal perforation smaller than
1%.
Moderate NA 269
37 PPIs, diet or topical steroids might be offered as
first line anti-inflammatory therapy. The choice
of therapy should be individually discussed with
the patient and might be potentially inter-
changeable over time. The efficacy of any ther-
apy should be checked by a follow-up
endoscopy after a 6- to 12-week initial course.
Endoscopic dilation should be considered in
Low Strongly in favor Expert opinion
(continued)
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eﬀectively down-regulates allergic Th2 inﬂammation in
PPI-REE patients,17,20,22 in a similar way to that seen in
EoE after topical steroid therapy. Moreover, PPI ther-
apy in PPI-REE patients can almost normalize the
overall genetic signature, similar to that found in EoE
patients.21 In addition, two recent series have reported
that EoE patients responsive to diet/topical steroids
may also achieve remission on PPI therapy.23,24
Collectively, growing evidence underscores that it may
be counterintuitive to separate PPI-REE from EoE
depending on a diﬀerent response to a single medica-
tion, when both disorders exhibit overlapping pheno-
typic, genetic, and mechanistic features. These evolving
considerations have been recently compiled in a
Position Paper endorsed by an international panel of
experts.12 Recently, the ﬁrst series of three patients with
symptoms and histologic features of EoE responsive to
vonoprazan has been published.25 Vonoprazan is a new
potassium-competitive acid blocker with a more potent
and sustained acid suppression than PPI therapy.
These novel ﬁndings underscore the importance of
GERD and targeting gastric acid output in a subset
of EoE patients, although it does not necessarily
exclude an antigen-mediated Th2 inﬂammatory
response.
What is the relationship between GERD and EoE?. Statement
3: EoE and GERD are diﬀerent entities and may coex-
ist, either unrelated or interacting bidirectionally.
LE: moderate. Agreement: 100%, votes: strongly
agree (100%).
Summary of evidence: GERD and EoE are the most
frequent esophageal diseases. Both conditions are more
common in young males, so their coexistence is plaus-
ible. Consequently, they are not mutually exclusive dis-
orders and may coexist in a single patient, albeit not
necessarily interacting. In a patient with symptoms of
esophageal dysfunction, a well-established diagnosis of
GERD based on endoscopic ﬁndings or pH monitoring
may not necessarily rule out EoE.
The interacting relationship between GERD and
EoE might be bidirectional and complex.26 It has
been suggested that GERD may contribute to the
pathogenesis of EoE by causing esophageal muco-
sal integrity changes, promoting trans-epithelial
allergen permeation and subsequent allergic immune
Table 1. Continued
Section and
number Statements
Level of
evidence
Strength of
recommendation Key references
patients with dysphagia/food impaction
unresponsive to anti-inflammatory treatment.
38 Azathioprine and 6-mercaptopurin might play a
role in inducing and maintaining long-term
remission in EoE in limited cases.
Low Weakly in favor 278
39 Sodium cromoglicate and antihistamines have no
effect on symptoms or esophageal eosinophilia.
Low Strongly against 63
40 There is insufficient evidence to recommend
montelukast, a leukotriene receptor antagonist,
in patients with EoE.
Moderate Strongly against 283, 284
41 First generation chemoattractant receptor- hom-
ologous molecule on Th2 cells (CRTH2) antag-
onists induces modest clinic and histologic
improvement in EoE.
High Weakly against 285
42 The anti-IL5 antibodies mepolizumab and reslizu-
mab have no effect on symptoms and modestly
reduce esophageal eosinophilia.
High Strongly against 286, 287, 288
43 QAX576, an anti-IL13 antibody, has no effect on
symptoms but reduces esophageal eosinophilia
and downregulates EoE transcripts in a sus-
tained manner.
High Weakly against 289
44 Omalizumab, an anti-IgE antibody, has no effect on
symptoms or esophageal eosinophilia.
High Strongly against 256
45 Infliximab, an anti-tumor necrosis factor alpha
antibody, has no effect on symptoms or
esophageal eosinophilia.
Low Strongly against 292
EoE: eosinophilic esophagitis; PPI: proton pump inhibitor.
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activation.20 However, this hypothesis remains unpro-
ven. EoE patients have been shown to have hypersen-
sitivy to the presence of intra-esophageal acid, with
lower thresholds for onset of symptoms and pain
after esophageal acid infusion when compared to
healthy volunteers.27 Esophageal mucosal integrity at
baseline is markedly impaired in EoE patients com-
pared to healthy controls.20 Since acid hypersensitivity
is strongly related to impaired esophageal mucosal
integrity, these structural changes may justify the
observed acid hypersensitivity. Acid hypersensitivity
might also explain symptom improvement or remission
on PPI therapy despite persistent esophageal inﬂamma-
tion in pediatric and adult EoE patients.11,13,17,28–31
Likewise, EoE may potentially induce architectural
and functional changes in the esophagus that can
induce GERD.26,30
What is the current incidence and prevalence of
EoE?. Statement 4: The incidence of EoE has increased
and currently varies widely from 1 to 20 new cases per
100,000 inhabitants per year (mean value 7). Prevalence
rates range between 13 and 49 cases per 100,000
inhabitants.
LE: Moderate. Agreement: 100%, votes: strongly
agree (93%).
Summary of evidence: Several studies aimed to esti-
mate the incidence and prevalence of the disease with
diﬀerent designs, including prospective and retrospect-
ive registries of cases, series of endoscopies and esopha-
geal biopsies, and population-based studies, have
consistently shown that the incidence and prevalence
of EoE have risen rapidly. Diﬀerent studies with diﬀer-
ent methodologies have shown that the current inci-
dence rate ranges between 6 and 13 new cases per
100,000 inhabitants-year in Europe,32–35 USA,36–38
and Canada.39,40
Regarding prevalence, an increase from 9.91 in 2000
to 42.96/100,000 inhabitants in 2003 was reported for
children.38 These last prevalence rates are consistent
with other recent studies in patients of all ages carried
out in USA,36,37,41,42 and in Europe (Spain,
Switzerland, and Denmark),32–35,43 which have shown
a gradual and signiﬁcant increase of up to 40–56 cases
per 100,000 inhabitants.
A pediatric population-focused systematic review
has estimated that the incidence of EoE in children
varied from 0.7 to 10/100,000 per person-year,44 while
prevalence ranged from 0.2 to 43/100,000.
A recent systematic review with meta-analysis of
population-based studies has shown an increase in the
overall incidence rates of EoE after 2008, being cur-
rently of 7.2 (95% CI 0.8–20.2) new patients/100,000
inhabitants yearly. The best estimates for current
pooled prevalence were 28.1 (95% CI 13–49) patient
per 100,000 inhabitants. It was also observed that the
incidence and prevalence rates were signiﬁcantly higher
in adults than children and in studies carried out in
America compared to Europe.45
What is the frequency of EoE in patients with esophageal
symptoms?. Statement 5: The frequency of EoE in
adults with esophageal symptoms undergoing an
upper endoscopy is 7%. This frequency may rise up
to 23% and 50% in patients with dysphagia and food
impaction, respectively. Further data in children are
required.
LE: moderate. Agreement: 100%, votes: strongly
agree (100%).
Summary of evidence: This question has been
addressed mostly in adult patients. The prevalence of
EoE was prospectively determined in 400 consecutive
adult patients with esophageal symptoms undergoing
routine upper endoscopy in the USA. The prevalence
of EoE in this cohort was 6.5% (25/385; 95% CI, 4.3–
9.4%) if the histologic cut-oﬀ was >20 eosinophils per
high power ﬁeld (eos/hpf) and increased to 7.3% when
the cut-oﬀ changed into >15 eos/hpf.46
The prevalence of EoE may vary depending on the
evaluated symptom.47 EoE is uncommon in patients
with refractory GERD symptoms (0.9–8%).48–52 In
adults with non-cardiac chest pain, EoE was found in
6% of the patients.53 EoE prevalence may rise up to
23% and 46% in patients undergoing upper endoscopy
for dysphagia and food impaction, respectively.15,54–59
In pediatric populations who underwent an upper
endoscopy for any indication, the prevalence of EoE
ranged from 2.3% to 6.8%, with a pooled prevalence
of 3.7% (95% CI 2.4–5.1).44 In children under 18 years
of age undergoing upper endoscopy for abdominal
pain, the frequency of EoE was 6%,60 and 14 of 376
children with refractory aerodigestive symptoms (3.7%)
were diagnosed as having EoE refractory to medical
treatment.61
What is the age of presentation of EoE?. Statement 6: EoE
may occur at any age with a rising incidence in children
with age and a peak in adults at 30–50 yrs.
LE: Moderate. Agreement: 100%, votes: strongly
agree (100%).
Summary of available evidence: EoE has been
reported throughout the life span, from infancy to
almost 100 years of age.62 However, most cases occur
in children, adolescents, and adults younger than 50
years. Available data mostly come from retrospective
studies in both pediatric and adult populations. As for
children, most studies coincide with peak incidence in
older children.37,38,63,64 Studies in adults have shown
that the majority of cases is clinically apparent at the
age of 30–50 years.33,36,37
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Is male gender a risk factor for EoE?. Statement 7: Male
gender is a strong risk factor for EoE both in children
and adults.
LE: High. Agreement: 100%, votes: strongly agree
(100%).
Summary of evidence: Nearly all studies have shown
that the prevalence of EoE is higher in males than in
females both in children and in adults.44,62,65–69 Male
predominance is shown in Europe,32,35,43,70,71 in the US
and Canada,37,46,62,67,72 and in some reports from the
East,73–75 with a low number of EoE cases. In a retro-
spective Australian study on children, 30 of 42 cases
who were reclassiﬁed as EoE were boys but the diﬀer-
ence was not statistically signiﬁcant.76 In contrast, in
another general population based endoscopy study
from northern Sweden with 1000 randomly selected
subjects with or without gastrointestinal symptoms
the prevalence of EoE was 1.1% and there was a
male predominance.77 In a recent meta-analysis of
EoE in children and adults in population-based studies
by Arias et al. there was a clear male predominance,
odds ratio (OR) 2.01 (95% CI 1.63–2.48).45 Although
twin and family studies have revealed strong environ-
mental and weaker genetic cues explaining heritability
of EoE,72 a gender-speciﬁc association between single
nucleotide polymorphisms (SNP) in thymic stromal
lymphopoietin (TSLP) gene as well as a nonsynon-
ymous SNP in the TSLP receptor has been suggested
as a mechanism for the male predilection of EoE.78 In
conclusion, male gender is a two- to threefold risk
factor for EoE.
Is EoE associated with atopy?. Statement 8: Rhinitis,
asthma, and eczema are signiﬁcantly more common in
EoE patients compared to the general population.
However, it remains unproven that atopy predisposes
to EoE.
LE: moderate. Agreement: 100%, votes: strongly
agree (100%).
Summary of evidence: EoE patients usually suﬀer
from a high number of concomitant atopic disorders
including rhinitis, asthma and eczema. A limited
number of studies have provided direct comparisons
of atopy between EoE and series of patients with
GERD, upper gastrointestinal symptoms or healthy
volunteers endoscopically assessed to exclude EoE, or
database-registered subjects.
A recent systematic review of 21 studies overall
including 53,592 adult and pediatric EoE patients and
54,759 controls found that the criteria for deﬁning a
diagnosis of atopy in either EoE patients or controls
was not structurally considered in most of the studies.
Despite this limitation, overall allergic rhinitis was
signiﬁcantly more common among EoE patients com-
pared to control subjects (OR 5.58; 95% CI 3.27–9.53),
as were bronchial asthma (OR 3.06; 95% CI 2.01–4.66)
and eczema (OR 2.86; 95% CI 1.88–4.36).79
Is EoE a food allergy and how does it relate with other food
allergies?. Statement 9: EoE is a distinct form of food
allergy. Immunoglobulin E (IgE)-mediated food aller-
gies are common in EoE patients.
LE: High. Agreement: 100%, votes: strongly agree
(100%).
Summary of evidence: From its early descriptions,
EoE was considered as a particular form of food allergy
in which the esophageal inﬂammatory inﬁltration
remitted after exclusively feeding patients with amino
acids-based elemental diets.80 A personal history of
atopy is documented prior to EoE diagnosis in
50–60% of cases.36,81,82 Most EoE patients are sensi-
tized to aeroallergens or food allergens, identiﬁed by
serum IgE measurements or by skin prick tests.83 On
the other hand, a small proportion of EoE patients do
not suﬀer from concomitant atopy, and therefore they
are not sensitized to foods nor aeroallergens. EoE
shows no relevant diﬀerences in these particular
patients, among whom oﬀending foods can be also
identiﬁed after empiric elimination diet and sequential
food reintroduction.84,85
The criteria used to deﬁne ‘‘food allergy’’ were
extremely variable, ranging from food sensitization
exclusively to food-induced anaphylaxis and even
celiac disease.79 Likewise, allergy tests used for deﬁn-
ing and diagnosing food allergy have yield variable
results when used in patients with EoE: 15–43% of
EoE patients also have IgE-mediated food aller-
gies,36,81 and even a high prevalence of anaphylaxis
has been documented in EoE patients,86 giving rise
to the hypothesis that the presence of IgE-mediated
food allergy might be considered a predictive factor
for the subsequent development of EoE in adult and
pediatric patients.87 Several case series have reported
patients undergoing oral immunotherapy for progres-
sive desensitization from IgE-mediated food allergy
that eventually developed EoE,88–90 whose risk has
been summarized in a meta-analysis to be 2.72%
(95%CI 1.7–4.0%).91 However, there is insuﬃcient
evidence on the relative risk of oral immunotherapy
for food allergies to induce de novo EoE. Once EoE is
accidentally triggered by oral immunotherapy, most
cases remit after discontinuation of oral immunother-
apy.88,92 The decision of whether discontinuing
immunotherapy or maintaining it while treating
pharmacologically EoE may depend on the severity
of the food allergy episodes (e.g. anaphylaxis)
intended to prevent.
Is EoE related with celiac disease?. Statement 10: EoE and
celiac disease are independent disorders.
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LE: High. Agreement: 100%, votes: strongly agree
(100%).
Summary of evidence: An association between celiac
disease and EoE has not been demonstrated in large
cross-sectional and population-based epidemiological
studies.93,94 A systematic review on this topic found
no support for the hypothesis of a true association,95
but evidence pointed toward the independent course of
both diseases, including the lack of a common genetic
basis and an eﬀectiveness for gluten-free diet in achiev-
ing histological remission of EoE in celiac patients of
only 32%,96 similar to that expected for wheat elimin-
ation in EoE patients. A signiﬁcant publication bias in
favor of short studies reporting positive associations
between both diseases was also documented.95
Does EoE predispose to other associated disorders?.
Statement 11: EoE appears to have no causal or tem-
poral relationship with hypereosinophilic syndromes,
inﬂammatory bowel disease (IBD), esophageal atresia,
and connective tissue disorders (CTDs).
LE: Low. Agreement: 100%, votes: strongly agree
(100%).
Summary of evidence: Esophageal involvement has
been described in some cases of eosinophilic gastro-
enteritis and other eosinophilic gastrointestinal dis-
orders (EGID).97,98 However, EoE largely remains as
a disorder indeﬁnitely restricted to the esophagus with
no cases later extending to distal GI segment described.
An anomalous T-lymphocyte clone expansion toward
the development of hypereosinophilic syndrome has
neither being described in the natural history of EoE.99
The concurrence of EoE and Crohn’s disease in two
patients led to speculation on the true relationship
between both disorders characterized by an idiopathic
dysregulated mucosa immune response causing inﬂam-
mation.100,101 In the ﬁrst reported case,100 EoE was
diagnosed 8 years after the patient had been suﬀering
from Crohn’s disease, while the second presented with
EoE 3 years before the onset of Crohn’s disease.101 IBD
and EoE are highly prevalent disorders in Westernized
countries, respectively aﬀecting 137–241 and 45–56
patients/100,000 inhabitants in Europe and
US;32,33,37,102–107 concomitances of both diseases in
the same patients are so rarely described that, from
an epidemiological point of view, they should be con-
sidered as completely independent disorders. The
expression of surface markers in blood eosinophils
from patients allow distinguishing IBD and EoE from
each other and from healthy controls,108 which pro-
vided additional evidence on the independence of
both diseases by the distinct patterns of activation sig-
nals from the inﬂamed tissues.
Several case reports and short series of children and
adolescents with esophageal atresia have suggested that
EoE appears as a concomitant problem among
them.109–113 A male predominance, frequent sensitiza-
tion to food and/or aeroallergens, and peripheral
eosinophilia are also observed in patients who share
both conditions, in whom eosinophilic esophageal inﬁl-
tration and symptoms also reverse after topic or sys-
temic steroids and after dietary therapy. Some genetic
connections between esophageal atresia and EoE have
been suggested by mice models that involves microdele-
tions in the Forkhead box (FOX) transcription factor
gene cluster. Speciﬁcally, the FOXF1 gene has been
involved in esophageal atresia and other anomalies,114
and binding sites for the FOXF1 protein include pro-
moter regions of proinﬂammatory genes as those for
eotaxins.115 Further research should establish the etio-
logical association between both conditions.
Retrospective database analyses have shown a link
between EoE and CTDs, including Marfan’s syndrome
(MFS), hypermobile Ehlers–Danlos syndrome (EDS),
and joint hypermobility syndrome (JHS), by the ﬁnding
of an unexpectedly higher than expected (8-fold) preva-
lence of EoE among patients with CTDs (relative risk:
8.1; 95% CI 5.1–12.9).116 The investigation of the
molecular connection of this association found muta-
tions in ﬁbrillin-1 (FBN1) and TGFBR1 genes, which
were related to an impaired epithelial barrier function
and excessive TGF-b signaling,117 respectively, with
both contributing to the EoE-CTD proposed pheno-
type. Further prospective research must conﬁrm the
aforementioned syndromic association and to establish
the particularities of EoE among these patients.
Section B. Diagnosis
What are the most common symptoms in EoE?. Statement
12: In older children and adults with EoE solid food
dysphagia, food impaction, and non-swallowing asso-
ciated chest pain are the most commonly reported
symptoms. In younger children and infants the most
common symptoms reported are reﬂux-like symptoms,
vomiting, abdominal pain, food refusal, and failure to
thrive.
LE: high. Agreement: 100%, votes: strongly agree
(100%).
Summary of evidence: Several studies describing pre-
senting symptoms of EoE clearly show a diﬀerent pat-
tern of clinical presentation between adults and young
children. In adults, dysphagia (70–80%) and food
impaction (33–54%) constitute the most common
symptoms. Other associated symptoms are heartburn,
regurgitation, chest discomfort and exercise-induced
chest pain.87,118–120
Clinical manifestations of EoE in infants and tod-
dlers mainly consist of non speciﬁc symptoms such as
reﬂux-like symptoms, vomiting, nausea, abdominal
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pain, food refusal, or failure to thrive.64 Older children,
usually over 10 years old, and adolescents might exhibit
dysphagia and food impaction like adult patients.
What is the appropriate biopsy protocol for diagnosing and
monitoring EoE?. Statement 13: At least six biopsies
should be taken from diﬀerent locations, focusing on
areas with endoscopic mucosal abnormalities.
LE: Moderate; SR: Strong in favor. Agreement:
100%, votes: strongly agree (100%).
Summary of evidence: Because inﬂammatory changes
in EoE are frequently patchy and may not be present in
all biopsies,121–125 it is recommended that at least
6 biopsies should be obtained from at least two diﬀer-
ent locations in the esophagus, typically in the distal
and proximal halves of the esophagus. Diagnostic sen-
sitivity increases with the number of biopsies and is
maximized after taking at least six biopsies.126–128
Esophageal biopsies should be targeted to areas of
endoscopic abnormality, mainly white exudates and
longitudinal furrows, which are associated with higher
peak eosinophil counts.121,122,129,130 Biopsies should
also be taken despite a normal endoscopic appearance
of the esophagus, which has been reported in up to
10–32% of adult and pediatric patients, respect-
ively.63,131 It is also advisable to obtain duodenal and
gastric mucosal biopsies at the moment of initial diag-
nosis in order to exclude eosinophilic gastroenteritis.
What is the accepted threshold for eosinophil mucosal density
for the diagnosis of EoE?. Statement 14: The accepted
threshold for eosinophil density for the diagnosis of
EoE is 15 eos/hpf (standard size of 0.3mm2) in
esophageal mucosa, taken as the peak concentration
in the specimens examined.
LE: Moderate; SR: Strong in favor. Agreement:
100%, votes: strongly agree (87%).
Summary of evidence: Having a histologic threshold
for the diagnosis of EoE is useful to make a distinction
from other inﬂammatory esophageal diseases. The 15
eos/hpf threshold was set to increase the uniformity of
EoE diagnosis,132–134 upon its capacity to reliably dis-
tinguish between EoE and GERD.87,135–139 GERD is
associated to low eosinophil counts, usually <5 eos/hpf,
but it is important to re-emphasize that GERD and
EoE are not mutually exclusive disorders and may
coexist. A sensitivity of 100% and a speciﬁcity of
96% for the diagnosis of EoE have been recently
shown with the cut-point of 15 eos/hpf.140
The selected 15 eos/hpf threshold, however, is some-
what arbitrary and clinical judgment is required to
interpret the signiﬁcance of borderline counts, as well
as counts compatible with EoE in asymptomatic
patients. Additional limitations to quantifying eosino-
phil counts are variability in the deﬁnition of an
intraepithelial eosinophil in hematoxylin stained tissue
sections and the lack of standardization of the size of a
high-power ﬁeld, since diﬀerent microscopes may have
diﬀerent high-power ﬁeld areas.132 Therefore, it may be
useful to report eosinophil density (eos/mm2) together
with the eosinophil count (eos/hpf); communication
with the pathologist upon questionable ﬁndings can
also be helpful in clinical practice.
As for histological assessment of EoE, are there other techni-
ques apart from hematoxylin-eosin staining?. Statement 15:
Hematoxylin-eosin (HE) staining is suﬃcient for histo-
logical assessment of EoE in routine clinical practice.
LE: Low. SR: Weakly against. Agreement: 100%,
votes: strongly agree (87%).
Summary of evidence: HE staining is suﬃcient for the
assessment of eosinophil counts and associated histo-
logic features in clinical practice. Speciﬁc techniques,
including immunochemistry,141–144 electron micros-
copy,145–147 and confocal microscopy following
immune ﬂuorescence staining,148 are currently per-
formed for research purposes only.
Which additional histological markers besides peak eosinophil
counts could be considered in the histological assessment of
EoE?. Statement 16: Besides peak eosinophil count,
additional histological features may include eosinophil
microabscesses, basal zone hyperplasia, dilated intercel-
lular spaces, eosinophil surface layering, papillary
elongation, and lamina propria ﬁbrosis.
LE: low. SR: Weakly in favor. Agreement: 100%,
votes: strongly agree (100%).
Summary of evidence: Currently, the histologic diag-
nosis of EoE relies on a peak count 15 eos/hpf
assessed within the epithelial stratum. However, other
histologic features that can be assessed in HE-stained
slides include eosinophil abscesses, basal zone hyper-
plasia, dilated intercellular spaces, eosinophil surface
layering, and papillary elongation of the squamous epi-
thelium.149 These histologic abnormalities are not spe-
ciﬁc for EoE and might be found in other esophageal
diseases, but tend to be more severe in EoE patients.
An EoE-speciﬁc histologic scoring system (EoEHSS)
has been recently developed, and in-site validated, to
provide a standardized method to evaluate esophageal
biopsies for features in addition to peak eosinophil
count (Supplementary table 2).150 Histologic abnorm-
alities were scored for severity (grade) and extent
(stage) in a four-point scale (0 normal; 3 maximum
change) for eight EoE-associated features, including
eosinophil density, basal zone hyperplasia, eosinophil
abscesses, eosinophil surface layering, dilated intercel-
lular spaces, surface epithelial alteration, dyskeratotic
epithelial cells, and lamina propria ﬁbrosis. A strong-
to-moderate agreement was found among the three
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pathologists who evaluated the biopsy samples. The
EoEHSS composite score better discriminated treated
from untreated patients than peak eosinophil count.
Interestingly, this score might be utilizable by patholo-
gists after minimal training, consisting of less than one
minute per biopsy slide. Lamina propria ﬁbrosis was
not included in the EoEHSS score because it was not
present in the majority of biopsies. However, it should
be also evaluated when available, since several EoE
therapies have demonstrated a potential ability to
reverse existing remodeling ﬁbrotic changes of the
esophagus.151–154
Are there less invasive diagnostic tests useful for diagnosing or
monitoring EoE?. Statement 17: Currently, noninvasive
biomarkers are not accurate to diagnose or monitor
EoE. Some minimal invasive diagnostic tools show
promise and merit further evaluation.
LE: moderate. SR: Strongly against. Agreement:
100%, votes: strongly agree (100%).
Summary of evidence: Finding a reliable none or
minimally invasive method to monitor disease activity
of EoE, therefore avoiding repeat endoscopies with
biopsies, has been largely pursuit. Only absolute
serum eosinophil count has been consistently shown
to signiﬁcantly correlate with the degree of esophageal
eosinophilia, and to signiﬁcantly decrease after steroid-
or PPI-induced histologic remission.155–161 However, its
diagnostic accuracy was only 0.754.160 Potential bio-
markers, including total IgE, eosinophil cationic pro-
tein,159–161 eosinophil-derived neurotoxin,156,161,162
mast cell tryptase,160 several chemokines,156,160 and
fractionated exhaled nitric oxide,163 have all failed to
diagnose or monitor the disease. Likewise, a compre-
hensive diagnostic panel of inﬂammatory factors
known to be associated with EoE pathogenesis was
not increased in the serum or correlated with response
to topic steroid treatment.164
As for minimally invasive devices, both the String
Test (a capsule ﬁlled with approximately 90 cm of
string) and the Cytosponge (an ingestible gelatin cap-
sule comprising compressed mesh attached to a string)
have shown preliminary good correlations with esopha-
geal eosinophilia degree and eosinophil-derived pro-
teins.165,166 These results should be further
corroborated in larger studies.
Are symptoms alone accurate to monitor disease activity in
EoE?. Statement 18: Symptoms do not correlate accur-
ately with histologic disease activity, so histology cur-
rently continues to be necessary to monitor the disease.
LE: moderate, SR: weakly in favor. Agreement:
100%, votes: strongly agree (100%).
Summary of evidence: Assessment of activity in EoE
includes patient-reported outcome (PRO) measures
(symptoms and quality of life), clinician-reported out-
come (ClinRO), and objective measures (laboratory,
endoscopic, and histologic ﬁndings).167 The lack of
validated instruments to assess EoE activity has deﬁn-
itely led to an inconsistent relationship between symp-
toms and esophageal inﬂammation in EoE
patients.29,157,168–170 In adult patients, EoE activity
can be currently assessed using the validated
Eosinophilic Esophagitis Activity Index (EEsAI) PRO
instrument.171 This index quantiﬁes the diﬃculties fore-
seen by patients with diﬀerent food consistencies, as
well as dietary or behavioral modiﬁcations for the
same food consistencies. Recently, a prospective multi-
center study has shown a modest predictive capacity of
distinct EEsAI cutoﬀ values to predict either histologic
or endoscopic remission.172 Therefore, clinicians should
not make assumptions about the biological activity of
EoE exclusively upon symptoms, and endoscopic
esophageal biopsies currently continue to be necessary
to accurately monitor the disease activity.
Alternative validated instruments for symptom
assessment are the Dysphagia Symptom
Questionnaire in adults and the pediatric EoE symptom
score (PEESS).173–175 Evaluation of EoE-related qual-
ity of life can also be helpful when assessing disease
activity. Currently validated questionnaires are the
EoO-QoL-A in adults and children and the PedsQL
in pediatric patients.176,177
A new endoluminal functional lumen imaging probe,
the EndoFLIP system, has initially demonstrated a sig-
niﬁcant reduction in esophageal distensibility in EoE
patients.178 This functional test has shown a lack of
correlation of eosinophil counts and esophageal disten-
sibility, partially explaining the dissociation between
inﬂammatory activity and symptoms in EoE.179
Furthermore, reduced esophageal distensibility pre-
dicted risk for food impaction,179 and correlated with
endoscopically identiﬁed ring severity.180 Whether the
addition of the EndoFLIP system to PRO measures can
enhance our accuracy to predict the real biological
activity of EoE warrants further investigation.
Are endoscopic findings important for diagnosing or monitor-
ing EoE?. Statement 19: Endoscopic ﬁndings alone do
not reliably establish a diagnosis of EoE. Their value
to assess disease activity needs further evaluation.
LE: low. SR: weakly in favor. Agreement: 100%,
votes: strongly agree (100%).
Summary of evidence: Several endoscopic ﬁndings
have been associated with EoE, either aﬀecting the
mucosal surface [edema or decreased vascularity (also
referred as loss of vascular pattern), longitudinal fur-
rowing, rings (also called trachealization), white pla-
ques (also referred as spots or exudates), and fragile
(or creˆpe paper) mucosa] or the esophageal caliber
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[strictures and narrow caliber esophagus]. A ﬁrst meta-
analysis including 4678 patients with EoE and 2742
non-EoE controls revealed modest sensitivity and nega-
tive and positive predictive values for endoscopic fea-
tures to predict esophageal inﬂammation.131 Of note,
the prevalence of endoscopic features was substantially
heterogeneous among the included studies.
Consequently, the EoE endoscopic reference score
EREFS (acronym for exudates, rings, edema, furrows,
and strictures) was proposed as a standardized tool to
classify and grade the presence and severity of the ﬁve
major endoscopically features of EoE.181 The EREFS
classiﬁcation system was validated in adult patients in a
prospective multicenter study, with good interobserver
agreement among practicing and academic gastroenter-
ologists.182 External validation of the EREFS system
showed consistent scoring between experts and trainee
endoscopists.183 Regarding the accuracy of the EREFS
system to diagnose and monitor EoE activity, conﬂict-
ing results have been shown in two recent single-center
studies.182,184 As such, larger multicenter studies are
required to ascertain the utility of the EREFS system
for disease activity assessment. All these data indicate
that endoscopists should not base a diagnosis of EoE,
neither to make assumption on the activity or remission
of this disease exclusively based on endoscopic ﬁndings.
Section C. Natural history
Is EoE clinically, endoscopically, histologically, and functionally
a progressive disorder?. Statement 20: Untreated EoE is
usually associated with persistent symptoms and
inﬂammation, leading to esophageal remodeling result-
ing in stricture formation and functional abnormalities.
There is some evidence that eﬀective anti-inﬂammatory
treatment may limit progression.
LE: moderate. Agreement: 100%, votes: strongly
agree (47%).
Summary of evidence: The ﬁrst prospective assess-
ment of a series of 30 adult patients with EoE with
an average of 7.2 years of follow-up documented that,
in the absence of anti-eosinophil treatment or elimin-
ation diets, dysphagia and esophageal eosinophilic inﬁl-
tration persisted over time. Subepithelial ﬁbrosis also
developed.99 For pediatric EoE, the ﬁrst data on its
natural history was evaluated in 89 children with an
8-year follow-up,185 founding EoE to be a chronic
and relapsing condition, as conﬁrmed in a large chart
review of 620 EoE patients (where 330 patients had a
greater than 1 year follow-up for analysis) at the
Children’s hospital of Philadelphia.64 While the major-
ity of young adults diagnosed with EoE during child-
hood continued to require pharmacologic treatment
and/or dietary modiﬁcation for EoE,186 recurrent
symptoms were present in 91% of the 32 adults
retrospectively followed for a 3.3 year period at Mayo
Clinic, leading to 61% of them to repeated treatment
with swallowed topical steroids at least once.187
The duration of an untreated disease, expressed as
diagnostic delay, constitute the major risk factors for
esophageal remodeling and stricture formation in EoE,
as nicely shown in retrospective studies. The analysis of
200 Swiss adult EoE patients show that delay in diag-
nosis determined the prevalence of ﬁbrotic esophageal
features, which increased from 46.5% in diagnostic
delay up to 2 years to 87.5% when it was >20
years.188 Similarly, a signiﬁcant diﬀerence in esophageal
diameter was determined by a delayed diagnosis in
adult EoE patients, ranging from <10 mm if EoE diag-
nosis was reached after 14.8 years to 17 mm when it
lasted only 5 years.189 Disease duration has been also
identiﬁed as the leading association for abnormalities in
high-resolution manometry in EoE patients.190 On the
other hand, patient’s age signiﬁcantly increases both
subepithelial collagen deposits and the likelihood of
ﬁbrostenotic disease.191 The OR for ﬁbrostenosis for
each 10-year increase in age was found to be 2.1
(95% CI 1.7–2.7).192 All these ﬁndings suggested that
the natural history of EoE represents a progression
from an inﬂammatory to a ﬁbrostenotic phenotype.
Some preliminary data are showing the ability of
both topic steroids and dietary treatment to reverse
esophageal remodeling in children, potentially avoiding
esophageal strictures by reversing epithelial mesenchy-
mal transition.151–154
Does EoE affect quality of life of patients?. Statement 21:
EoE signiﬁcantly impacts health-related quality of life
of patients, impairing their social and psychological
functioning.
LE: moderate. Agreement: 100%, votes: strongly
agree (100%).
Summary of evidence: EoE may have a profound
eﬀect on the quality of life and psychosocial adjustment
of aﬀected children and their families, including social
diﬃculties, anxiety, sleeping diﬃculties, depression, and
school problems.193,194 Scores measuring health-related
quality of life are signiﬁcantly worse in pediatric
patients with more pronounced esophageal symp-
toms,195 in children with active histologic disease and
those treated with dietary restrictions.177 Impairment of
quality of life persists over time, even 15 years after
following the initial diagnosis,196 and improves during
the course of evaluation and treatment.195 Patients with
less symptom severity were those who showed the most
improved quality of life scores.195
As for adult patients, psychosocial domains are
aﬀected, but not physical wellbeing or mental function-
ing.197 Anxiety mainly derives from concerns related to
the disease itself (uncertainty about the long-term
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consequences of a chronic illness, fears of disease pro-
gression, long-term medication), highly restrictive diet-
ary modiﬁcations and swallowing diﬃculties/choking
hampering social interactions.197 Similar to those ﬁnd-
ings observed in children, quality of life in adult
patients with EoE is worse in patients with more symp-
tom severity and biological disease activity.198
Does EoE progress into malignancy?. Statement 22: There
is no evidence that EoE is a pre-malignant condition.
LE: Moderate. Agreement: 100%, votes: strongly
agree (93%).
Summary of evidence: Anecdotal case reports had
suggested a relationship between esophageal neoplasia
and esophageal eosinophilia,199,200 but neither patient
fulﬁlled diagnostic criteria for EoE. Therefore, esopha-
geal eosinophilia was likely tumor-associated inﬂam-
mation. Esophageal eosinophilia (not necessarily EoE)
has been also associated with Barrett’s esopha-
gus.201–206 In a series of 13 adult patients, no patient
developed esophageal dysplasia or carcinoma after
follow-up for a mean period of 13.6 years (range 5–24
years).207 As for children with EoE, the expression of
p53 and Ki-67 (early markers of esophageal dysplasia)
on immunochemistry was found to be signiﬁcantly
increased compared to both children with normal
esophagus and GERD, but was reduced following med-
ical therapy and not associated with dysplasia.208
Section D: Treatment
Is PPI therapy effective in inducing remission of
EoE?. Statement 23: PPI therapy induces clinical and
histological remission in a proportion of pediatric and
adult patients with EoE.
LE: moderate, SR: strong in favor. Agreement:
100%, votes: strongly agree (93%).
Summary of evidence (see Supplementary table 3):
From 2006 to 2010, several retrospective case series
and studies highlighted the existence of patients with
clinical, endoscopic and histological features compat-
ible with EoE showing clinicopathological response to
PPI therapy.28,57,209,210 In 2011, a ﬁrst large prospective
study in adult patients with a similar proﬁle reported a
50% response after an 8 week course of PPI therapy.11
Of note, response to PPI therapy was observed in 80%
and 33% of patients with pathological and normal
esophageal acid exposure on pH monitoring,
respectively.11
Since then, several RCTs and prospective studies
have fully corroborated remission rates on PPI therapy
ranging from 33% to 36%,14,15, 211,212 when histo-
logical remission was deﬁned by <5 to 7 eos/hpf. Of
note, remission rates increased to 50% and 57% when
histological remission was redeﬁned as <15 eos/
hpf.14,211 A ﬁrst review article in 2013 revealed response
to PPI therapy was signiﬁcantly commoner with docu-
mented GERD when compared to patients with nega-
tive pH monitoring (70% vs. 29%, p< 0.001).213 The
ﬁrst prospective study conducted in pediatric patients
has lately shown a 47% rate of histological remission
on PPI therapy.214
A recent systematic review with meta-analysis,
including 33 studies with 619 patients with suspected
EoE, has shown that PPIs led to histological remission
(deﬁned by <15 eos/hpf) in 50.5% (95% CI 42.2–
58.7%) and symptomatic improvement in 60.8%
(95%CI 48.38–72.2%) of cases.215 No signiﬁcant diﬀer-
ences were noted in patients’ age, study design, and
type of PPI assessed. A trend towards increase eﬃcacy
was observed when PPI was administered twice daily
compared to once daily, and among patients with a
pathological pH monitoring.215 However, the authors
cautioned about the interpretation of these ﬁndings,
due to poor-quality evidence (a majority of case reports
and retrospective studies, with no placebo-controlled
trials so far), heterogeneity in results and publication
bias in favor of studies reporting histological responses
to PPI therapy. Recommended PPIs doses in adults are
omeprazole 20–40 mg twice daily or equivalent; in chil-
dren, 1–2 mg/kg or equivalent.
Is PPI therapy effective to maintain remission in
EoE?. Statement 24: In PPI responders, long-term PPI
therapy is eﬀective in maintaining remission.
LE: low, SR: Strong in favor. Agreement: 100%,
votes: strongly agree (87%).
Summary of evidence: When pharmacological treat-
ment for EoE is stopped, symptoms and/or esophageal
eosinophilia typically recur over a 3–6 month period.4
However, the long-term therapeutic strategy and best
maintenance doses for pharmacologic therapies are yet
to be deﬁned. An approach where the dose is progres-
sively decreased to the lowest dose that keeps the dis-
ease in remission seems reasonable until more data are
available.216
Until recently, the sustained eﬃcacy of PPIs in chil-
dren was limited to two retrospective series only com-
prising six patients with PPI-REE, all with recurrence
of esophageal eosinophilia and symptoms over time
while on maintenance PPI therapy.217,218 A recent pro-
spective study has ﬁrst shown that most PPI-REE pedi-
atric patients (78%) remain in clinic-pathologic
remission at one-year follow up on maintenance PPI
low doses.214 As for adults, a ﬁrst long-term follow-
up multicenter study including 75 patients has been
lately published.219 All patients who temporarily dis-
continued PPI therapy had symptom and/or histo-
logical relapse. The majority of patients (73%)
maintained histological remission after at least 1 year
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on tapering PPI dosage to the minimum eﬀective clin-
ical dose. Among relapsers, most regained histological
remission after dose escalation, suggesting some
patients continue to require maintenance high-dose
PPI. Another series from Spain has lately corroborated
these ﬁndings, with 80% of patients keeping response
to PPI therapy after tapering doses.220 No data for >1
year of follow up are available yet.
Are systemic steroids recommended in EoE?. Statement 25:
Systemic steroids are not recommended in EoE.
LE: moderate, SR: Strongly against. Agreement:
93%, votes: strongly agree (87%).
Summary of evidence: An RCT conducted in children
compared the eﬃcacy and safety of oral prednisone (1
mg/kg/dose twice a day) with swallowed ﬂuticasone
propionate (2 puﬀs 4 times/day; 110 mg per puﬀ for
ages 1–10 years and 220 mg per puﬀ for ages 11 years
or older,) for 12 weeks.221 Both agents were equally
eﬀective in achieving initial histological and clinical
improvement at week 4, after which drugs were pro-
gressively tapered. However, systemic eﬀects (hyper-
phagia, weight gain, and/or cushingoid features) were
noted in 40% of patients in the oral prednisone arm,
whereas the only relevant side eﬀect for topical steroids
was esophageal candidiasis, present in 15% of patients.
Are topical steroids effective in inducing remission of
EoE?. Statement 26: Topical corticosteroids are eﬀective
for induction of histological remission in both pediatric
and adult EoE patients.
LE: High, SR: strongly in favor. Agreement: 100%,
votes: strongly agree (100%).
Summary of evidence (see Supplementary table 4):
Currently, 11 randomized trials conducted in children
and adults,157,168–170,211,212,221–225 which have been
summarized in several systematic reviews and meta-
analyses,226–229 conﬁrm the eﬃcacy of topical steroid
therapy for histologic remission in EoE patients
(Supplementary table 5). Variability regarding inclu-
sion criteria, agents (ﬂuticasone/budesonide), daily dos-
ages, length of treatment (from 2 to 12 weeks), delivery
system (swallowed puﬀs from inhalers, suspension, vis-
cous slurry, eﬀervescent tablets), and deﬁnition of
histologic remission (from <1 to <20 eos/hpf) notably
hampers comparative analyses among these studies.
The currently recommended drugs and doses are sum-
marized in Supplementary table 6.
As for the delivery system, a milestone study com-
pared budesonide 1 mg twice daily for 8 weeks given in
nebulized and viscous preparations.223 Complete histo-
logic remission was signiﬁcantly higher (64% vs. 27%)
in the oral viscous budesonide group. Overall drug
mucosal contact time, measured by means of nuclear
scintigraphy, was signiﬁcantly longer in patients treated
with the oral viscous budesonide and this diﬀerence was
signiﬁcantly higher in the distal esophagus. Therefore,
this important study pointed out the histologic
improvement was directly related to higher mucosal
contact time and highlighted the importance of appro-
priate drug delivery methods in the treatment of EoE.
Presently, the higher histologic remission rates in ran-
domized control trials have been accomplished with
eﬀervescent tablets and oral viscous budesonide.225
Unlike histologic remission, data on symptom reso-
lution are less clear. Several clinical trials have not been
able to demonstrate a statistically signiﬁcant advantage
of topical corticosteroids over placebo,168–170,224,225 or
even performed worse than PPI therapy.211
Furthermore, two recent meta-analysis could not eluci-
date a clear trend in symptom improvement with top-
ical steroids as compared with placebo.228,229 Several
reasons can explain this discrepancy between histologic
and clinic outcomes, including diﬀerences in patient
selection, deﬁnitions of symptom response, steroid for-
mulations and duration of treatment. Symptom assess-
ment in EoE can be troublesome due to use of diﬀerent
non-validated symptom-scoring tools, the subjective
nature of assessment of clinical response, changes in
symptom proﬁle in the transition from childhood to
adulthood, behavioral adaptations masking symptoms
(solid food avoidance, prolonged meal times and exces-
sive mastication), and symptoms related to ﬁbrosteno-
tic features or lack of esophageal distensibility, which
may not be inﬂuenced by inﬂammation healing.
Are long-term topical corticosteroids effective in maintaining
EoE in remission?. Statement 27: In steroids responsive
patients, long-term therapy with topical corticosteroids
is eﬀective in maintaining remission in a proportion of
patients.
LE: low, SR: Strongly in favor. Agreement: 100%,
votes: strongly agree (100%).
Summary of evidence: Up to now, a single rando-
mized, double-blind, placebo-controlled trial has eval-
uated the eﬃcacy of long-term topical steroid treatment
for EoE.230 Twenty-eight adult patients were rando-
mized to oral budesonide suspension 0.5 mg/day or
placebo for 50 weeks. At the end of the study period,
complete remission (<5 eos/hpf) was documented in
36% of patients in the budesonide group, while no
patient in the placebo group remained in complete
remission. Possibly, low-dose maintenance budesonide
dosage in this trial underrated the long-term eﬀective-
ness of topical steroid therapy.
As for children, an extension of treatment in a rando-
mized, double-blind, placebo-controlled trial has been
lately reported.224 Those patients who achieved complete
remission (<1 eos/hpf in both distal and proximal
esophagus) with high-dose ﬂuticasone (1760 mcg/day)
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received a 50% dose reduction for three months and
were re-evaluated. Sustained response was documented
in 73% of initial responders. A more recent prospective
study in children responders (<15 eos/hpf) to swal-
lowed ﬂuticasone from metered dose inhaler revealed
that long-term administration of similar doses led to
sustained remission to 59% and 63% of patients
during months 13–24 and >2 yrs of follow-up,
respectively.231
Are topical steroids safe drugs in the treatment of eosinophilic
esophagitis?. Statement 28: Swallowed topical cortico-
steroids seem to have a favorable safety proﬁle in the
treatment of EoE, with no serious side eﬀects reported.
Esophageal candidiasis, mostly incidental, may occur in
up to 10% of patients.
LE: moderate. Agreement: 100%, votes: strongly
agree (100%).
Summary of evidence: Although the numbers of
patients with EoE involved in individual trials with
ﬂuticasone propionate and budesonide are low, the
overarching number of recruited patients allows a per-
spective on a large cohort of treated patients. No stat-
istically signiﬁcant diﬀerent adverse events (AEs)
compared to placebo were found in the majority of
RCTs comparing topical steroids to placebo, except
for esophageal candidiasis, which were reported
in 5–26% of EoE patients assigned to active interven-
tions in short term/induction of remis-
sion,157,168,170,211,221,223,225 and in 0–5% in long-term/
maintenance trials.222,230 Esophageal candidiasis were
asymptomatic in all cases and constituted an inciden-
tal ﬁnding in scheduled endoscopies, which may also
imply the higher monitoring level of patients in short
compared to long-term trials. As a treatment (when
reported) oral nystatin or oral ﬂuconazole were used.
There were no diﬀerences in the risk of esophageal
candidiasis for nebulized versus viscous topic budeso-
nide.223 According to a recent meta-analysis of RCTs,
a NNH of 9 for developing an asymptomatic esopha-
geal candidiasis was calculated.229 No RCTs reported
severe AEs.
Some uncertainty ranges around suppression of sys-
temic cortisol levels induced by topical steroid treat-
ment, especially in children. In short-term RCTs 24 h
urine and/or serum cortisol levels were not sup-
pressed.168,224,225 Information on long-term eﬀects of
swallowed topical steroids on adrenal suppression in
children is being provided by observational studies
including short series of EoE patients with disagreeing
results: While no diﬀerences in serum cortisol levels
were found following treatment with swallowed ﬂutica-
sone propionate (range 220–880 mg daily) and budeso-
nide (range 0.5–1 mg daily), along treatment lengths of
8–43 weeks,232 an additional study showed that adrenal
suppression was present in 10% of children treated with
swallowed glucocorticoids for 6 months and was
found only in those treated with FP >440 mg daily.233
Finally, 43% of children presented suboptimal stimu-
lated cortisol, independently of treatment duration.234
No clinical sign of adrenal insuﬃciency or growing
impairment have been reported so far.231
Until more information is available, cortisol moni-
toring to prevent adrenal insuﬃciency could be advis-
able for children with EoE if they are receiving high
doses of swallowed topic steroids for long periods, or
concomitant use of inhaled/nasal corticosteroids for
associated atopic diatheses.
Is there a place for elemental diet in the clinical management
of EoE patients?. Statement 29: There is a limited place
for elemental diet in EoE, which should only be con-
sidered after failure of properly performed medical
treatment and/or elimination diet. Elemental diet
induces histologic remission in up to 90% of pediatric
and adult EoE patients. There is limited information
regarding symptoms.
LE: Low, SR: Weakly against. Agreement: 100%,
votes: strongly agree (83%).
Summary of evidence (see Supplementary table 7):
The ﬁrst evidence on the eﬃcacy of a dietary interven-
tion for inducing remission of EoE was provided with
elemental diet. In ten children with severe esophageal
eosinophilia attributed to GERD and refractory to
other therapies, exclusive feeding with an amino acid-
based formula devoid of antigenic capacity was given
for a minimum of six weeks,80 while avoiding all kind of
table foods. Clinic and histologic remission was
observed in 8 children, whereas the remaining two
patients showed symptomatic and histologic improve-
ment. Subsequent reports have repeatedly conﬁrmed
the eﬃcacy of elemental diet in patients of all
ages.63,235–238 Despite the absence of any RCT, a
recent meta-analysis has shown that the overall eﬀect-
iveness of elemental diet among observational studies in
inducing histological remission of EoE is 90.8% (95%
CI 84.7–95.5%), with no diﬀerences between age
groups.239 In contrast, there is limited evidence on the
ability of elemental diets to achieve symptomatic
improvement: In a large prospective pediatric series
elemental diets induced clinical improvement of EoE
after only 8.53.8 days;235 in adults, elemental diet
achieved histological remission in around 2 weeks.238
However, and despite outperforming all other diet-
ary or topic steroid-based treatments in terms of eﬃ-
cacy,239,240 several disadvantages impact on the use of
elemental diets in clinical practice, including its poor
palatability, which requires using nasogastric tubes in
most of children,63 and lack of adherence in up to one-
third of adults recruited for a 4-week trial.238
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A complete avoidance of all kind of table food deter-
mines feelings of being diﬀerent from their family and
peers in children and aggravates the eating/diet and
social impacts of EoE,241 which are major determinants
of health-related quality of life (QoL) in adults.176,242
The cost of elemental formulas is also high and not
universally covered by health insurances. All these
drawbacks would increase in long-term use.
A potential role for elemental diets has been pro-
posed after failure to empiric six-food elimination
diets in patients who wish to further investigate the
causality of unusual foods and potential involvement
of aeroallergens in EoE.243 However, this option has
not been assessed yet in clinical practice or research.
Therefore, the multiple disadvantages of amino acid
formulas in EoE relegate their only realistic utility to
small children who are not yet taking solid food if
symptoms and inﬂammation persist and no narrowing
is appreciated, especially if a rapid clinical improve-
ment is required.
What is the efficacy of food allergy testing-based elimination
diet for inducing histologic remission in EoE?. Statement 30:
Food allergy testing-based elimination diet induces
histologic remission in less than one third of adult
patients. This rate may be higher in pediatric patients.
LE: moderate, SR: Strongly against. Agreement:
100%, votes: strongly agree (100%).
Summary of evidence (see Supplementary table 7):
Food allergy testing-based elimination diet stands for
eliminating foods with positive results on skin prick
tests (SPT) and atopy patch tests (APT). In 2002, an
elimination diet combining SPT and APT, excluding an
average of ﬁve foods, ﬁrst induced clinic and histologic
remission in 49% of pediatric patients.244 Causative
foods were exclusively attributed by symptom recur-
rence after food reintroduction, with no biopsy evalu-
ation. A decade later, the same research group updated
their results with an overall eﬃciency of 53%.245
Nevertheless, several studies have further reported
worse results with this strategy in children and adult
patients.63,236,246–248 A meta-analysis revealed that this
dietary approach led to histologic remission in 45.5%
of patients (95% CI 35.4–55.7%), with wide heterogen-
eity (I2: 75%) indicating a low reproducibility.239 The
eﬃcacy rates were signiﬁcantly lower in adults than in
children (32.2% vs. 47.9%).
More recently, a pilot study in adults evaluating an
elimination diet guided by blood IgE microarrays (e.g.
measuring IgE levels to food protein components) was
interrupted early due to poor eﬃcacy (7% histologic
remission).249 A recent study also in adults evaluated
the accuracy of the combination of multiple allergy skin
and blood tests, measuring either immediate or delayed
hypersensitivity responses, to detect oﬀending foods in
adult EoE patients.250 Similarly, no allergy test could
accurately predict food triggers identiﬁed through food
challenge with histologic reassessment in responders to
a six-food elimination diet.
Should allergy testing be used to identify causative food trig-
gers of EoE?. Statement 31: The utility of allergy tests in
the identiﬁcation of food triggers of EoE is consistently
low in adults and variable in children.
LE: Low, SR: Strongly against. Agreement: 100%,
votes: strongly agree (100%).
Summary of evidence: Because food-speciﬁc serum
IgE can be detectable in some individuals even in the
absence of clinical reactions to the particular food, SPT
assessing both the presence and the function of mast
cell-bound IgE represents the standardized and vali-
dated technique to study immediate allergic reac-
tions.251 In contrast, APT is used to assess the
presence of non-IgE, cell-mediated reactions.252 No
study has incorporated skin biopsies to verify the pres-
ence of an immunologic inﬁltrate at the cutaneous site
of a positive APT result for food to validate this tech-
nique in EoE;253 besides, APT performance is not stan-
dardized and interpretation is subjective with a
signiﬁcant interobserver variation.
As also described in IgE-mediated food allergy,254
negative predictive values (NPV) of skin testing for
foods are generally superior to the positive predictive
values (PPV) in EoE patients. Assessment of diagnostic
accuracy of skin allergy testing in pediatric EoE has
provided PPV for SPT ranging from 26.3% to 86.3%
depending on the food (average of 47%),245 while NPV
were >90% for multiple foods, with the exception of
egg, wheat, soy (range 79–90%), and milk (30%).
Predictive values for APT followed a similar trend,
with PPV ranging from 12% to 86.2% (average 44%),
and NPV >90% with the exception of milk (31%). A
NPV >90% for SPT means that there is a greater than
90% chance that the patient will not have an IgE-
mediated reaction; a NVP >90% for APT almost
excludes a delayed food hypersensitivity reaction. The
combination of SPT and APT for building an elimin-
ation diet increased the sensitivity rates of skin testing
(65–95%, with the exception of milk and pork, which
were in the 50% range) as well as speciﬁcity rates for all
foods (78–90%).237 That combination yielded an aver-
aged PPV poor (44%), but increased the average NPV
(92%), with the exception of milk (44%).245 However,
others have found slightly lower NPV values for milk,
egg, and wheat – the most common food triggers for
EoE – (being 40%, 56%, and 67%, respectively).237
The fact that EoE is deﬁned as a food allergy in a
vast majority of patients excludes the validity of such
methods in identifying EoE food triggers. Besides, as
ATP has not been validated in food allergy, variability
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in NPV in APT results can be attributable to the dif-
ferent thresholds established by diﬀerent authors for
considering a result as positive. SPT in EoE might
also reﬂect cross-reactivity with environmental aller-
gens, and not directly a food sensitization (grass allergy
may present wheat-speciﬁc IgE). An extremely low con-
cordance between SPT results and food triggers of EoE
identiﬁed by biopsy-monitored sequential food reintro-
duction has been repeatedly provided.84,85
Additionally, cumulative data support the current
thought that EoE is primarily non-IgE mediated,255
but associated to IgG4,256–258 and according to avail-
able evidences, IgE testing via SPT or serum is very
unlikely to provide meaningful data for generating a
foundation for elimination diets.
As a consequence, the diagnostic accuracy of skin
allergy tests is insuﬃcient to design eﬀective diets for
EoE patients, or to support the development of dietary
advancement in EoE.259
What is the efficacy of empiric six-food elimination diet for
inducing histologic remission in EoE?. Statement 32: An
empiric six-food group elimination diet (SFED) induces
histologic remission in around three quarters of pediat-
ric and adult patients.
LE: moderate, SR: weakly in favor. Agreement:
100%, votes: strongly agree (87%).
Summary of evidence (see Supplementary table 7):
The eﬃcacy of an empiric elimination diet in EoE
was ﬁrst reported in 2006, aiming at overcoming both
the unfeasibility of elemental diet in clinical practice
and the low sensitivity/speciﬁcity of allergy skin testing
to identify EoE food triggers. It consisted of eliminat-
ing the six foods most commonly associated with food
allergy in the pediatric population in Chicago (cow’s
milk protein, wheat, egg, soy, peanut/tree nuts, ﬁsh,
and seafood).236 In this ﬁrst seminal study, the so-
called SFED achieved clinical and histologic remission
in 74% of children (74%). Similar results have been
further obtained in patients of all ages.84,85,237,247 A
recent meta-analysis on seven observational studies
provided an extremely homogenous (I2 statistic ¼ 0)
histologic remission rate of around 72% (95% CI 66–
78%) in children and adult patients.239 The high level
of dietary restriction and the large number of endosco-
pies after individual food reintroduction that this six-
food elimination diet requires counteract its eﬀectiveness
and wide reproducibility in clinical practice.
Aside from a six-food elimination diet, are there simpler
empiric dietary strategies for EoE?. Statement 33: In adult
patients, an empiric four-food elimination diet (FFED)
achieves remission in half of the patients, whereas a
two-food elimination diet (TFED; animal milk and
gluten-containing cereals) may be still eﬀective in
40% of patients.
LE: moderate, SR: weakly in favor. Agreement:
100%, votes: strongly agree (87%).
Summary of evidence: The moderate-to-high eﬀect-
iveness and wide reproducibility of SFEDs are counter-
acted by several drawbacks,239 namely the high level of
dietary restriction and the large number of endoscopies
after individual food reintroduction. Of note, the
majority (65%–85%) of patients responders to a
SFED were found to have just 1 or 2 causative foods
after six food challenges and endoscopies
(Supplementary table 8).84,85,260,261 The most common
causative foods identiﬁed after a response to a SFED
have been cow’s milk, wheat, egg, and, to a lesser
extent, soy/legumes, with a negligible role for nuts,
ﬁsh, and seafood. Upon this rationale basis, it was
developed the FFED, avoiding the most common
food triggers in EoE (cow’s milk, wheat, eggs, and leg-
umes).261 A ﬁrst prospective multicenter study in adult
patients showed a 54% remission in adults,261 whereas
an abstract in pediatric population revealed a 71% eﬃ-
cacy.250 In both studies, cow’s milk was the most
common food trigger (especially in children). Half of
adult responders were found to have cow’s milk, wheat
or both as food triggers,262 whereas 74% of pediatric
patients had a single food trigger.250 Accordingly, a
step-up approach (in other words, eliminating at ﬁrst
the one or two most common food triggers and subse-
quently increasing the level of restriction in non-
responders) should be further evaluated in EoE. In
this respect, cow’s milk elimination diet in children
has been recently reported to achieve histological remis-
sion in 65% and 61% of patients in two studies, albeit
both studies were ﬂawed by methodological
issues.263,264 An upcoming study, only available in
abstract form, has ﬁrst evaluated the eﬃcacy of a
TFED (animal milk and gluten-containing cereals),
stepping up to FFED and SFED.265 A TFED achieved
EoE remission in 38 patients (40%), whereas remission
rates increased to 52% and 65% with a FFED and
SFED, respectively. Among responders to a TFED,
the most common food triggers were animal milk
(60%), gluten-containing cereals (25%) and both
(15%). Compared to starting with a SFED, this step-
up strategy allowed reducing endoscopic procedures
and the diagnostic process time by 35%.
Is long-term avoidance of food triggers effective to maintain
EoE in remission?. Statement 34: Prolonged avoidance of
triggering foods may lead to drug-free sustained clinical
and histological remission of EoE.
LE: Low; SR: Strong in favor. Agreement: 100%,
votes: strongly agree (100%).
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Summary of evidence: Once the food or foods
responsible for EoE in each individual patient has
been identiﬁed, long-term avoidance has been recom-
mended in order to maintain disease remission.266,267
In contrast with the abundant literature that has eval-
uated the eﬀectiveness of dietary modiﬁcation in
achieving EoE remission, the sustained eﬃcacy of
avoiding consumption of food responsible of the dis-
ease has been assessed limitedly, with no documents
speciﬁcally targeted to report on this topic, so the avail-
able evidence on it has been provided with scarce
details as secondary outcomes of observational and
quasi-experimental research addressed to additional
goals.
Two studies conducted in adults reported that all the
patients who did not take the food(s) responsible for
the disease remained asymptomatic,84,85 and with histo-
logic remission in esophageal biopsies for a period of
up to three years,85 making drug treatment unneces-
sary. Despite some persistent isolated eosinophils in
the esophageal inﬁltration (being in all case its density
below the diagnostic threshold) other histopathological
features of active EoE, such as epithelial hyperplasia,
were not present after one year on the dietary elimin-
ation.84 The involvement of two or more foods in the
origin of EoE in adults was reported as hampering a
complete adherence to a prolonged food avoidance
maintenance therapy, that although eﬀective, was sub-
stituted by a drug-based treatment allowing a liberal-
ized diet.24
In children, a follow up of up to 4 years of mainten-
ance under food triggers avoidance has been reported
for ﬁve children,260 after which they were rechallenged
with food antigens they had reacted to during the initial
food reintroduction phase, showing EoE recurrence in
most of cases. Empiric SFED-based therapy has
showed no treatment-related complications and none
of the children demonstrated nutrient deﬁciencies or
growth deceleration during the dietary reintroduction
phase,260 and neither after a year of progressive reintro-
duction of eliminated foods.268 No study has appropri-
ately evaluated the eﬀect of long-term food avoidance
on the natural history of EoE, especially regarding the
reversion of ﬁbrous remodeling phenomena,152 and nei-
ther the impact of continuously avoiding common
foods that usually cause the disease on the health-
related QoL of EoE patients.
What is the efficacy of endoscopic dilation in treating
EoE?. Statement 35: Endoscopic dilation improves dys-
phagia in up to three quarters of adult EoE patients
with reduced esophageal caliber, without having an
eﬀect on the underlying esophageal inﬂammation.
LE: Moderate, SR: Strong in favor. Agreement:
100%, votes: strongly agree (100%).
Summary of evidence: The eﬀectiveness of esopha-
geal dilation in patients with EoE have been mostly
reported in retrospective and single-center studies, the
results of which were summarized in a meta-analysis of
nine studies overall including 525 adult patients who
underwent to 992 dilation procedures.269 Clinical
improvement was documented in 75% (95% CI 58–
93%, I2 ¼ 86%) of patients. The duration of the
eﬀect in terms of clinical relief was variable. Only
four studies have reported post-dilation caliber that
was 13 mm of average.270–273 No diﬀerences were
reported according to the dilation device used.
Available information on children is limited.274
Can endoscopic dilation be considered as a safe procedure in
the treatment of EoE?. Statement 36: Endoscopic dilation
in EoE is a safe procedure, with a risk of esophageal
perforation smaller than 1%.
LE: moderate. Agreement: 100%, votes: strongly
agree (100%).
Summary of evidence: A systematic review of the lit-
erature has assessed the rate of complications, including
esophageal perforation, death, hemorrhage, and post-
procedural chest pain, after 992 endoscopic dilations
performed in 525 adult EoE patients.269 A total of
three esophageal perforations (0.3%) and one hemor-
rhage (0.1%) were reported, all from the same institu-
tion,275 and no death was reported. Accordingly, the
rate of major complications is consistent with that
reported for endoscopic dilation in other esophageal dis-
eases.276 Post-procedural chest pain has been reported in
up to three quarters of patients when asked directly
before discharge from the endoscopy room,270 but
decreased to 2% by chart review.269 Deep mucosal
rents or laceration should not be reported as endoscopic
complications, seeing as they are the intended outcome.
More studies are required in children.
How to choose a therapeutic option for an EoE
patient?. Statement 37: PPIs, diet, or topical steroids
might be oﬀered as ﬁrst line anti-inﬂammatory therapy.
The choice of therapy should be individually discussed
with the patient and might be potentially interchange-
able over time. The eﬃcacy of any therapy should be
checked by a follow-up endoscopy after a 6- to 12-week
initial course. Endoscopic dilation should be considered
in patients with dysphagia/food impaction unrespon-
sive to anti-inﬂammatory treatment.
LE: low, SR: strong in favor. Agreement: 100%,
votes: strongly agree (100%).
Summary of evidence: Although there are no
approved medications by regulatory authorities yet,
solid data supporting all treatment categories have
been published over the last decade. EoE is a chronic
disease in which the esophageal inﬂammation
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progresses over time to esophageal ﬁbrotic remodeling,
leading to narrow caliber esophagus (caliber <13 mm)
and esophageal strictures.188,192 Patients may present
with an inﬂammatory, a ﬁbrostenotic or a mixed
phenotype. Histological features may remit with treat-
ment of PPI therapy, topical steroids or elimination
diets, whereas ﬁbrostenotic features can be solved by
means of endoscopic dilation. Making an analogy
with therapeutic considerations on IBD,277 all EoE
patient should receive a treatment targeted to cure
esophageal inﬂammation (mucosal healing) plus endo-
scopic dilation in case of ﬁbrostenotic endoscopic ﬁnd-
ings. The eﬃcacy of any pharmacological/dietary
therapy should be checked by means of a follow-up
endoscopy after a 6- to 12-week initial course.4 In add-
ition, all patients with ﬁbrostenotic abnormalities
(including narrow caliber esophagus <13 mm and stric-
tures) should be oﬀered endoscopic dilation, preferably
after a trial of medical/pharmacological therapy.277
Endoscopic dilation should not be the only therapeutic
intervention, as it has no eﬀect on the underlying
esophageal inﬂammation.207 As for patients with
severe symptomatic esophageal strictures, initial ther-
apy with topical steroids and endoscopic dilation
might rapidly achieve remission of clinic, endoscopic,
and histologic features.
The proposed therapeutic algorithm for EoE is sum-
marized in Figure 1. At the present time, it is well
known that PPI therapy leads to clinical and histo-
logical (<15 eos/hpf) remission in half of patients
with suspected EoE.215 Due to its safety proﬁle, ease
of administration and high response rates. PPI therapy
can be considered a ﬁrst-line treatment, although the
choice of therapy should be made after the patient is
informed about the pros and cons of alternative thera-
pies, such as diet and topical steroids.12 Treatments
might be interchangeable, seeing as two recent series
have reported that EoE patients responsive to diet/top-
ical steroids may also achieve further remission on PPI
therapy and viceversa.23,24 In case of unresponsiveness
to PPI therapy, a choice between topical steroid or diet-
ary therapy should be made. The choice should be once
again individually discussed with the patient and their
relatives and may depend on the age (adolescent and
young adults usually show poor adherence to diet), the
severity of the disease (severe symptoms should be trea-
ted with topical steroid therapy) or the patient’s life-
style and preferences or their ability to understand food
label information.277 Once the therapy is instituted, the
choice might be changed over time due to treatment
side eﬀects or the unwillingness of the patient to con-
tinue the medication (topical steroid therapy) or
Long-term treatment with an effective 
anti-inflammatory drug or diet
Patient with confirmed EoE
No remission Histologic remission, 
with persistent 
symptoms
Rule out other conditions unrelated 
to esophageal inflammation
Reevaluation of the initial diagnosis
Endoscopic 
dilation
*In patients with persistent symptoms under anti-inflammatory therapy, endoscopic dilation should be considered
** Refer the patient to an EoE center  
   CONSIDER  ONE AMONG THESE THERAPEUTIC OPTIONS*
SWALLOWED TOPIC STEROIDS ELIMINATION DIETPPI THERAPY
Clinic and histologic 
remission
No remission**
Elemental diet
Experimental drugs
Check the efficacy 
of alternative 
anti-inflammatory 
treatments above
Strictures/narrow caliber esophagus
Yes No
Figure 1. Therapeutic algorithm proposed for eosinophilic esophagitis in clinical practice.
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negative impact on quality of life and family resources
(dietary interventions).
What is the efficacy of immunomodulators in treating
EoE?. Statement 38: Azathioprine and 6-mercaptopurin
might play a role in inducing and maintaining long-
term remission in EoE in limited cases.
LE: low, SR: weakly in favor. Agreement: 100%,
votes: strongly agree (100%).
Summary of evidence: To date, only one case series on
the eﬃcacy of azathioprine or 6-mercaptopurin for EoE
has been published.278 These drugs exerted a positive
steroid-sparing eﬀect and induced and maintained
long-term steroid-free remission in three steroid-
dependent adults with active EoE (one patient with
eosinophilic gastroenteritis and esophageal involvement).
What is the efficacy of anti-allergic drugs in EoE?. Statement
39: Sodium cromoglicate and antihistamines have no
eﬀect on symptoms or esophageal eosinophilia.
LE: low, SR: strongly against. Agreement: 100%,
votes: strongly agree (100%).
Statement 40: There is insuﬃcient evidence to recom-
mend montelukast, a leukotriene receptor antagonist,
in patients with EoE.
LE: moderate, SR: strongly against. Agreement:
100%, votes: strongly agree (38%).
Statement 41: First generation chemoattractant
receptor-homologous molecule on Th2 cells (CRTH2)
antagonists induce modest clinic and histologic
improvement in EoE.
LE: high, SR: weakly against. Agreement: 100%,
votes: strongly agree (93%).
Summary of evidence: Several anti-allergic drugs
eﬀective in rhinitis and asthma have failed to show a
relevant impact on EoE-related symptoms or esopha-
geal inﬂammation. Despite a role for mast-cells has
been recognized in EoE,279,280 a 4-week trial of
sodium cromoglicate, a mast cell inhibitor, did not
prove either symptomatic or histologic improvement
in 14 children with EoE.63
Montelukast, a leukotriene D4 receptor antagonist,
use at high doses (10–100 mg) in adults,281 and stand-
ard ones in chidren,282 led to some symptomatic
improvement in open-labeled trials, with no patients
achieved histologic response. In a recent RCT, monte-
lukast was not superior to placebo to maintain remis-
sion from EoE after steroid therapy at 20 mg/daily
doses.283 Montelukast also failed to maintain topic ster-
oid-induced remission in a prospective series of adults
with EoE, with reappearance of symptoms and eosino-
philic inﬂammation within a 3-month period.284
Finally, the eﬃcacy of OC000459, a selective antag-
onist of CRTH2, has been recently assessed in a
randomized, double-blind, placebo-controlled trial con-
ducted in 26 adult EoE patients. Compared to placebo,
OC000459 100 mg bid for 8 weeks led to a signiﬁcant
decrease in symptom scores and esophageal inﬂamma-
tion density, but no normalization of esophageal biop-
sies was documented.285
Is there a role for biologic drugs in the treatment of
EoE?. Statement 42: The anti-IL5 antibodies mepolizu-
mab and reslizumab have no eﬀect on symptoms and
modestly reduce esophageal eosinophilia.
LE: high, SR: strongly against. Agreement: 100%,
votes: strongly agree (79%).
Statement 43: QAX576, an anti-IL13 antibody, has
no eﬀect on symptoms but reduces esophageal eosino-
philia and downregulates EoE transcripts in a sustained
manner.
LE: high, SR: weakly against. Agreement: 100%,
votes: strongly agree (86%).
Statement 44: Omalizumab, an anti-IgE antibody,
has no eﬀect on symptoms or esophageal eosinophilia.
LE: high, SR: strongly against. Agreement: 100%,
votes: strongly agree (93%).
Statement 45: Inﬂiximab, an anti-tumor necrosis
factor alpha antibody, has no eﬀect on symptoms or
esophageal eosinophilia.
LE: low, SR: strong against. Agreement: 100%,
votes: strongly agree (100%).
Summary of evidence: Several biologic agents,
approved or under investigation for severe asthma,
have also been evaluated in EoE. The eﬃcacy of
mepolizumab and reslizumab, anti-IL5 monoclonal
antibodies, has been assessed in three randomized,
double-blind, placebo controlled trials involving chil-
dren, adolescents and adults with active EoE.286–288
Compared to placebo, no symptomatic improvement
was observed in two in three studies.286,288 All trials
documented a signiﬁcant reduction of esophageal
eosinophilic inﬁltration, but with no histologic remis-
sion observed.
QAX576, an anti-IL13 antibody, has been recently
evaluated in a randomized, double-blind, placebo con-
trolled trial in adult EoE patients.289 No signiﬁcant symp-
tomatic improvement was observed, albeit QAX576 led
to a reduction of mean eosinophil count by 60% and
downregulated gene expression of EoE-relevant esopha-
geal transcripts for up to 6 months after treatment.
Other anti-IL-13 drugs are currently under evaluation.
Despite some observational studies reporting clinical
beneﬁt from omalizumab, an anti-IgE antibody, in EoE
patients,290,291 a recent randomized, double-blind, pla-
cebo controlled trial in adult patients demonstrated no
relevant eﬀects on esophageal symptoms or eosino-
philia compared to placebo.256
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Finally, inﬂiximab, an anti-tumor necrosis factor
administered at doses 5 mg/kg body weight, at weeks
0 and 2, did not lead to symptom or histologic improve-
ment at week 6 in a case series of three adult EoE
patients.292
Conclusions and future perspectives
The value of these guidelines lies in widespread use and
implementation. Follow-up on the implementation pro-
cess will be made one year after commencement by
monitoring the degree of adherence to proposed state-
ments and recommendations through information at
EoE connect (www.eoeconnect.eu), the European regis-
try and database of EoE.
Content of these guidelines will be translated into the
diﬀerent European languages and published in the
national medical journals, which are routinely read by
the members of the national medical societies.
Educational meetings, pocket cards and guideline
apps are known to be useful tools and will be used in
the implementation process.
The rapid development in this area, especially
regarding therapeutic procedures and concerning bio-
markers motivates the working group’s aim to review
and update the guideline after three years from the pub-
lication date. The unmet needs that have arisen during
the development of these guidelines should be
addressed in the upcoming years and are summarized
in Supplementary table 9.
Finally, education is a key feature in the management
of EoE and should be heavily promoted to health pro-
fessionals and caregivers, as well as to patients and
families. Developing and validating educational tools
will further the establishment of vertical and horizontal
networks between Centers of Excellence, gastroenter-
ology and allergy specialists, pediatricians, pathologists,
nutritionists, and primary care practitioners.
Implementation at the community level should be in
partnership with the patient organizations.
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